Filgotinib's Long-Term Safety Profile in RA Patients Updated

Long-term study evaluated filgotinib, a Janus kinase-1 inhibitor, in 3,691 patients with moderate-to-severe rheumatoid arthritis. Filgotinib was administered at 100 mg or 200 mg daily over a median of 3.8 years (12,541 patient-years). The incidence rates of treatment-emergent adverse events (TEAEs), including serious infections, malignancies, major adverse cardiovascular events, and venous thromboembolism, remained stable and similar across doses. Herpes zoster incidence was lower with the 100 mg dose. In patients aged ≥65 years, the 100 mg dose was associated with numerically lower rates of non-melanoma skin cancer, malignancies excluding non-melanoma skin cancer, and all-cause mortality compared to the 200 mg dose.